Urology is the specialty that learned to treat without the knife.

In December 1980, The Lancet published a report on a new way to remove a kidney stone. Until then, a stone that would not pass meant an operation. The report described shock waves, aimed at the stone from outside the body. The waves broke the stone into fragments, and the fragments passed out in the urine. It worked in 20 of 21 patients. The side effects were a little blood in the urine and the odd bout of colic as the fragments came down. Many patients needed no general anaesthetic. A kidney stone no longer meant a scalpel.

Eleven years later, in October 1991, the New England Journal of Medicine published a trial that turned a vaccine on a cancer. Superficial bladder cancer keeps coming back after it is cut out. The trial gave 262 patients either a chemotherapy drug, doxorubicin, washed into the bladder, or BCG, the tuberculosis vaccine, washed into the bladder and injected under the skin. After five years, 37% of the BCG patients were free of disease, against 17% on chemotherapy. For cancer confined to the bladder lining, 70% responded completely to BCG, against 34%. BCG caused more fever and bladder irritation, but rarely anything severe. The immune system had been recruited against a cancer, and it had won.

Seven years after that, in May 1998, the same journal published two trials of a pill for erectile dysfunction. The pill was sildenafil, sold as Viagra. The first trial gave 532 men one of three doses or placebo for 24 weeks. The second gave 329 men the pill or placebo, raising the dose as needed. In the last month of the second trial, 69% of attempts at intercourse succeeded on the pill, against 22% on placebo. The price was headache, flushing and indigestion, in 6 to 18% of men. A condition men rarely spoke of now had a pill that worked.

These are three of the thousands of studies that shaped modern urology. They taught urology that shock waves could do the work of a scalpel, that a vaccine could hold back a cancer, and that a pill could treat what men would not discuss, and each time the answer was in a paper years before it was in a textbook.

It is still happening. Recently, in February 2026, the New England Journal of Medicine published the final survival results of a trial in men whose prostate cancer had come back after treatment, shown only by a rising blood test. The trial gave them leuprolide, the standard hormone injection, alone or with a daily pill, enzalutamide. After eight years, 78.9% of the men on the combination were alive, against 69.5% on leuprolide alone. A cancer found only by a number could now be held off for years. Practice follows the literature as it goes. It is a good culture. It has exactly one cost.